Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals
Executive Summary
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.
You may also be interested in...
Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals
Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.
Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces
Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.
Incoming EMA Chief Throws Weight Behind Antimicrobial Resistance Fight
Antimicrobial resistance, the lack of new antibiotics, and preserving the effectiveness of existing ones are high on the agenda for the soon-to-be new head of the European Medicines Agency, Emer Cooke.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: